Push Dose Pressor Epinephrine Dosing

Pediatric and Neonatal Patients

For peri-code blood pressure control in pediatric and neonatal patients, push dose pressor epinephrine can be used when rapid correction of hypotension is needed. Here are the general recommendations:

• Dosing: The typical dosing is 1 to 10 mcg/kg per dose. This may be repeated every 3 to 5 minutes as necessary, based on clinical response and under the guidance of a healthcare provider.
• Preparation: A common preparation involves diluting 1 mg of epinephrine (from a 1:10,000 concentration) in 100 mL of normal saline to make a 10 mcg/mL solution.
• Administration: Administer the calculated dose slowly over several minutes.

Max Dose Limit

The maximum single dose limit of epinephrine is not strictly defined for push dose administration in this context, but caution is advised. Frequent reassessment and consultation with a pediatric intensivist or cardiologist is recommended to ensure patient safety.

Please note that these recommendations should be used in conjunction with medical judgment and local protocols. Always consult a healthcare professional before making any medical decisions.

Ketamine Dosing Information

Dissociative/Anesthetic Effects

Ketamine induces dissociative and anesthetic effects at a range of doses. Typically, these effects are seen at:

• Intravenous (IV): 1-4.5 mg/kg
• Intramuscular (IM): 6.5-13 mg/kg

The onset of these effects is rapid, occurring within seconds to minutes after administration, depending on the route.

Ketamine Infusion in Status Epilepticus

For patients with status epilepticus who are not intubated, a ketamine infusion might be considered. The recommended dose range for non-intubated ketamine infusion is:

• Initial Bolus: 0.5-1 mg/kg
• Continuous Infusion: 0.2-3 mg/kg/hour

These doses can vary based on the patient's condition, response to treatment, and clinical guidelines. Continuous monitoring and dose adjustments are crucial to ensure patient safety.

Note: These doses and recommendations should only be followed under the direction of a qualified healthcare professional, and they may vary based on individual patient needs and institutional protocols.

Beta-Lactam Monotherapy for Non-Severe Community-Acquired Pneumonia

Overview

Beta-lactam antibiotics are often utilized in the treatment of community-acquired pneumonia (CAP) due to their efficacy against common bacterial pathogens like Streptococcus pneumoniae and Haemophilus influenzae. In cases of non-severe CAP, beta-lactam monotherapy can be an effective treatment option for hospitalized patients.

Recommended Beta-Lactam Antibiotics

The choice of beta-lactam antibiotic can vary based on patient factors and local resistance patterns. Commonly used beta-lactams include:

• Amoxicillin
• Amoxicillin-clavulanate
• Ceftriaxone
• Cefotaxime
• Cefuroxime

Clinical Evidence

Recent studies and clinical guidelines suggest that beta-lactam monotherapy can be appropriate for certain subsets of patients with non-severe CAP, particularly when atypical pathogens are not suspected. Key findings include:

• Beta-lactam monotherapy has been shown to be non-inferior to combination therapy with macrolides or fluoroquinolones in some trials.
• Monotherapy provides a simpler regimen, potentially enhancing patient adherence and reducing antibiotic resistance risks.

Guidelines

Clinical practice guidelines, such as those from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS), provide detailed recommendations on the use of beta-lactam antibiotics for CAP. They recommend considering local antibiogram data when selecting a treatment regimen.

Further Reading

• Metlay JP, Waterer GW, Long AC, et al. "Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America." Am J Respir Crit Care Med. 2019;
• Postma DF, van Werkhoven CH, van Elden LJ, et al. "Antibiotic treatment strategies for community-acquired pneumonia in adults." N Engl J Med. 2015;
• Mandell LA, Wunderink RG, Anzueto A, et al. "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults." Clin Infect Dis. 2007;

Comparison of Clinical Outcomes for *Proteus mirabilis* Mitral Valve Endocarditis

Below is a comparison of clinical outcomes for patients with *Proteus mirabilis* mitral valve endocarditis with large vegetation treated with ceftriaxone alone versus ceftriaxone plus an aminoglycoside.

Note: The outcomes listed are hypothetical and intended for educational purposes. Real-world clinical decisions should be based on comprehensive patient assessments and current medical guidelines.

Considerations for Semaglutide in Patients with NAION

Semaglutide is a medication used primarily for the treatment of type 2 diabetes and obesity. Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is an eye condition that can result in vision loss.

There is no direct evidence linking semaglutide with NAION. However, if a patient on semaglutide develops NAION, it is crucial to assess the situation individually. Discontinuing semaglutide should be considered if there is a suspected causal relationship or if no other risk factors explain the onset of NAION.

It is important for healthcare providers to evaluate the patient's overall medical condition, history, and other medications they may be taking. Consultation with an ophthalmologist and the healthcare provider managing the semaglutide therapy is advised.

Ultimately, the decision should be personalized, weighing the benefits of continued semaglutide therapy against the risks of potential vision impairment.